Write in a clean editor, then format for Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration in one click — DocuGuru applies the official Taylor & Francis template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration is a peer-reviewed journal published by Taylor & Francis, covering Amyotrophic Lateral Sclerosis Research, Neurogenetic and Muscular Disorders Research, Parkinson's Disease Mechanisms and Treatments.
| Publisher | Taylor & Francis |
|---|---|
| Reference style | Author–year (Chicago, T&F) Author–year — (Smith, 2023) in the text Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 12 (3): 45–58.
Formats any DOI in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration style. No sign-up. |
| Publishes research in | Amyotrophic Lateral Sclerosis Research Neurogenetic and Muscular Disorders Research Parkinson's Disease Mechanisms and Treatments Genetic Neurodegenerative Diseases Neurological diseases and metabolism |
| ISSN | 2167-8421 |
| Citation impact (2-yr) | 2.01 |
| h-index | 74 |
| i10-index | 734 |
| Total citations | 30,653 |
| Top institutions publishing here | University of Sheffield |
| Journal website | www.tandfonline.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
This article presents the revised consensus criteria for the diagnosis of frontotemporal dysfunction in amyotrophic lateral sclerosis (ALS) based on an international research workshop on frontotemporal dementia (FTD) and ALS held in London, Canada in June 2015. Since the publication of the Strong criteria, there have been considerable advances in the understanding of the neuropsychological…
This study presents the Edinburgh Cognitive and Behavioural ALS Screen (ECAS), developed for ALS patients with physical disability for use by health care professionals. The screen is designed to detect the specific profile of cognition and behaviour changes in ALS and to differentiate it from other disorders. Forty-eight ALS patients (none with evident dementia), 40…
Our objective was to confirm the efficacy and safety of edaravone in amyotrophic lateral sclerosis (ALS) patients. We conducted a 36-week confirmatory study, consisting of 12-week pre-observation period followed by 24-week treatment period. Patients received placebo or edaravone i.v. infusion over 60 min for the first 14 days in cycle 1, and for 10 of…
Bulbar motor deterioration due to amyotrophic lateral sclerosis (ALS) leads to the eventual impairment of speech and swallowing functions. Despite these devastating consequences, no standardized diagnostic procedure for assessing bulbar dysfunction in ALS exists and adequate objective markers of bulbar deterioration have not been identified. In this paper, we consider objective measures of speech motor…
